Patients with either HLA-A1 or HLA-A2 positivity were allowed in the trial, but what they found is that the vaccine was only effective for patients who were HLA-A2 positive. The results for that group have been very good (esp for those with MGMT methylation), and they are moving to a phase 3 trial soon (last quarter 2015).
Latest press release regarding the randomized phase 2 trial of ICT-107 is here:
ReplyDeletehttp://investors.imuc.com/releasedetail.cfm?releaseid=851605
Patients with either HLA-A1 or HLA-A2 positivity were allowed in the trial, but what they found is that the vaccine was only effective for patients who were HLA-A2 positive. The results for that group have been very good (esp for those with MGMT methylation), and they are moving to a phase 3 trial soon (last quarter 2015).
http://investors.imuc.com/releasedetail.cfm?ReleaseID=920623